Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number at other companies

Schering-Plough logo
Schering-PloughSGP
——
PTH
Pelthos TherapeuticsPTHS
——

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.97B+40.7%
Enterprise value$2.86B+36.8%
P/S4.9×-2.2×

Profitability

See full
Gross margin79.8%—
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026.

Filed
Feb 23, 2026, 4:11 PM EST
Fiscal year
FY2025
Accession
0001819790-26-000019
Line itemNumber of SharesWeighted-Average Exercise Price/Share ($)Weighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value ($)(1)
Outstanding - December 31, 20245,007,90819.296.91180,669
Granted583,23645.78
Exercised(307,192)20.64
Forfeited(52,827)24.66
Outstanding - December 31, 20255,231,12522.116.26312,647
Vested - December 31, 20253,868,85817.765.52248,052
Unvested - December 31, 20251,362,26734.468.3564,594

Item 8. Financial Statements and Supplementary Data

FAQ

What is Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
Tarsus Pharmaceuticals, Inc. (TARS) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number of $3.87M in Q4 2025.
How has Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number increased by 15.5% year-over-year, from $3.35M to $3.87M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number?
Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number has grown at a 55.3% compound annual growth rate (CAGR), from $428.49K to $3.87M.
What does share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number mean?
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

Ask your AI about Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude